Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01939054|
Recruitment Status : Unknown
Verified June 2015 by Binghe Xu, Chinese Academy of Medical Sciences.
Recruitment status was: Recruiting
First Posted : September 11, 2013
Last Update Posted : June 4, 2015
Chinese Academy of Medical Sciences
Biotech Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Binghe Xu, Chinese Academy of Medical Sciences
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||September 2015|
|Estimated Study Completion Date :||September 2016|